Endostar

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Lung CancerNasopharyngeal Carcinoma

199 competitors in Lung Cancer

#DrugCompanyPhaseTrials

1

Keytruda

Merck & Co.

Phase 3

322

Imfinzi

AstraZeneca

Phase 3

253

Opdivo

Bristol-Myers Squibb

Phase 3

204

Tagrisso

AstraZeneca

Phase 3

175

Beyfortus

BeiGene

Phase 3

106

Yervoy

Bristol-Myers Squibb

Phase 3

107

Abraxane

Bristol-Myers Squibb

Phase 3

78

Imjudo

AstraZeneca

Phase 3

69

Tecentriq

Roche

Phase 3

610

Alunbrig

Takeda

Phase 3

4Show 34 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma6 trials

Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma

Completed·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT02237924·120 enrolled

A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma

Completed·—·Phase 2·NCT02444949·75 enrolled

Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma

Unknown status·JJiangsu Cancer Institute & Hospital·Phase 2·NCT03932266·73 enrolled

Show 3 more trials

Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma

Unknown status·JJiangxi Provincial Cancer Hospital·Phase 2·NCT05177237·30 enrolled

Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 3·NCT02907710·300 enrolled

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Active, not recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT06055816·40 enrolled

Non-Small Cell Lung Cancer5 trials

Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

Unknown status·NNanjing NingQi Medicine Science and Technology Co., Ltd.·Phase 4·NCT02513355·400 enrolled

Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer

Completed·SShandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd·Phase 2·NCT00708812·126 enrolled

A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)

Unknown status·SSimcere Pharmaceutical Co., Ltd·Phase 4·NCT01028729·120 enrolled

Show 2 more trials

Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)

Completed·FFudan University·Phase 2·NCT01687439·15 enrolled

A Prospective, Single-arm Exploratory Clinical Study of SRT Combined With Envafolimab and Endostar in the First-line Treatment of Driver Gene-negative Advanced Non-small Cell Lung Cancer With PD-L1 Positive Expression

Not yet recruiting·TThe First People's Hospital of Lianyungang·Phase 2·NCT07818304·61 enrolled

Esophageal Cancer3 trials

Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer

Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT03649945·186 enrolled

Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial

Terminated·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT02749526·70 enrolled

Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients

Unknown status·Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 2·NCT01368419·40 enrolled

First-line Treatment3 trials

Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma

Unknown status·NNanjing NingQi Medicine Science and Technology Co., Ltd.·Phase 4·NCT02513342·400 enrolled

Endostar First-line Treatment of Advanced NSCLC

Unknown status·—·Phase 2·NCT03123445·150 enrolled

Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC

Unknown status·TThe First People's Hospital of Lianyungang·Phase 2·NCT05203276·40 enrolled

Esophageal Squamous Cell Carcinoma2 trials

Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Unknown status·FFudan University·Phase 2·NCT02665702·76 enrolled

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Completed·FFudan University·Phase 2·NCT03797625·52 enrolled

29 more indications

Chemotherapy2 trials

Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

Unknown status·XXinqiao Hospital of Chongqing·Phase 3·NCT02579564·134 enrolled

PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy

Unknown status·Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT04942301·24 enrolled

Soft Tissue Sarcoma2 trials

Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma

Completed·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03121833·52 enrolled

Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma

Unknown status·PPENG YUAN·Phase 2·NCT01812018·30 enrolled

Small Cell Lung Cancer2 trials

Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)

Completed·SShandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd·Phase 2·NCT00912392·138 enrolled

A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients

Completed·Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT01531790·19 enrolled

Locally Advanced1 trial

Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT01158144·134 enrolled

Pneumonia1 trial

Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis

Completed·XXinqiao Hospital of Chongqing·Phase 2·NCT03796364·126 enrolled

Gastrointestinal Tumors1 trial

Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors

Unknown status·NNanjing First Hospital, Nanjing Medical University·Phase 2·NCT06301828·16 enrolled

Brain Metastases1 trial

Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases

Unknown status·Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 2·NCT01410370·80 enrolled

PD-1 Inhibitors1 trial

Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC

Unknown status·DDong Wang·N/A·NCT04063449·170 enrolled

Neuroblastoma1 trial

Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma

Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT02615106·60 enrolled

Lung Cancer1 trial

SBRT With S1 Combined With Endostar in the Treatment of Lung Cancer

Unknown status·PPeking University Third Hospital·N/A·NCT04274270·60 enrolled

Head and Neck1 trial

A Trial of Endostar in Patients With Carcinoma of the Head and Neck

Unknown status·CChina International Medical Foundation·Phase 2·NCT02902432·24 enrolled

Cervical Cancer1 trial

CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04121975·82 enrolled

Intravenous1 trial

Rh-Endostatin (Endostar®) Continuous Intravenous Infusion

Unknown status·—·Phase 2·NCT03706703·50 enrolled

Metastasis1 trial

Endostar Combine With Radiotherapy in Brain Metastasis of NSCLC

Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT03614065·50 enrolled

NSCLC1 trial

Study of Endostar Subcutaneous Injection in NSCLC

Unknown status·Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT02652234·8 enrolled

Osteosarcoma1 trial

A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma

Unknown status·SShandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd·Phase 2·NCT01002092·160 enrolled

Adjuvant Treatment1 trial

Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment

Unknown status·YYong Chen·Phase 2·NCT04699214·210 enrolled

Gastric Cancer1 trial

Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer

Unknown status·TTang Xushan·Phase 3·NCT02008422·120 enrolled

Cervical Carcinoma1 trial

Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma

Completed·YYong Zhang,MD·Phase 2·NCT03086681·120 enrolled

Cutaneous Melanoma1 trial

Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

Unknown status·FFudan University·Phase 2·NCT05907512·43 enrolled

Metastatic Colorectal Cancer1 trial

Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT01832948·30 enrolled

Breast Cancer1 trial

Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT03907098·50 enrolled

Lung Adenocarcinoma1 trial

The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar

Unknown status·SSimcere Pharmaceutical Co., Ltd·Phase 2·NCT01564329·20 enrolled

Colorectal Cancer1 trial

Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT00853684·44 enrolled

Lymphoma1 trial

Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study

Unknown status·NNanjing NingQi Medicine Science and Technology Co., Ltd.·Phase 2·NCT02520219·60 enrolled

Pleural effusion1 trial

Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

Completed·Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 2·NCT01327235·336 enrolled

Efficacy and Safety1 trial

The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients

Unknown status·FFujian Cancer Hospital·Phase 3·NCT02865304·80 enrolled

Pancreatic Cancer1 trial

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

Unknown status·TThe Affiliated Hospital of Xuzhou Medical University·Phase 2·NCT05298020·20 enrolled

Nasopharyngeal Cancinoma (NPC)1 trial

Platinum-Free Neoadjuvant Chemotherapy Combined With Risk-Adapted Therapy in Nasopharyngeal Carcinoma: A Phase II Trial

Not yet recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT07794488·145 enrolled

Details

Drug Info

Related News